BiotechTube

MR13A9 + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uremic Pruritus

Conditions

Uremic Pruritus

Trial Timeline

Jan 16, 2021 โ†’ Sep 26, 2022

NCT ID
NCT04711603

About MR13A9 + Placebo

MR13A9 + Placebo is a phase 3 stage product being developed by Kissei Pharmaceutical for Uremic Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT04711603. Target conditions include Uremic Pruritus.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04711603Phase 3Completed
NCT03802617Phase 2Completed

Competing Products

15 competing products in Uremic Pruritus

See all competitors
ProductCompanyStageHype Score
CrovalimabChugai PharmaceuticalPhase 3
77
CrovalimabChugai PharmaceuticalPhase 3
77
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
IptacopanNovartisPhase 3
77
Iptcaopan 200 mgNovartisPhase 3
77
IptacopanNovartisPhase 3
77
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
51
CCX168AmgenPhase 2
51
Stage I:HSK21542 0.05 ฮผg/kg + Stage I:HSK21542 0.15 ฮผg/kg + Stage I:HSK21542 0.30 ฮผg/kg + Stage I:HSK21542 0.80 ฮผg/kg + Stage II:HSK21542 0.3 ฮผg/kg + Stage II:HSK21542 0.6 ฮผg/kgHaisco Pharmaceutical GroupPhase 2
49
CemdisiranAlnylam PharmaceuticalsPhase 2
49
cemdisiran + PlacebosAlnylam PharmaceuticalsPhase 2
49
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
28
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60

Other Products from Kissei Pharmaceutical

KAD-1229 + Placebo + InsulinApproved
84
Avacopan, prednisolone and rituximab + Prednisolone and rituximabApproved
84
KLH-2109 + LeuprorelinPhase 3
76
KAD-1229Phase 3
76
KUC-7483 + Placebo + TolterodinePhase 3
76